This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
- 73 views
- 36 downloads
Development and optimization of nanodelivery of novel inhibitors of ERCC 1 /XPF for enhanced cancer therapy
-
- Author(s) / Creator(s)
-
This research investigates the potential of using the malaria drug pyronaridine (PYD) and its liposomal formulation (LPY) to sensitize cancer cells to treatment. Specifically, it targets the ERCC1/XPF enzyme complex crucial for DNA repair, making cancer cells more responsive to radiation therapy and platinum-based chemotherapy. Preliminary findings indicate a potential synergistic effect when combining PYD with cisplatin in certain cancer cell lines (FaDu and H1299). However, further research is needed to confirm and compare these effects with free PYD. This approach holds promise for enhancing cancer treatment strategies by inhibiting ERCC1/XPF and enhancing chemotherapy sensitivity.
-
- Date created
- 2023-05-18
-
- Subjects / Keywords
-
- Type of Item
- Conference/Workshop Poster